查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587286

大肠直肠癌药物市场：按药物类别、治疗类型、给药途径、分销管道划分 - 全球预测 2025-2030

Colorectal Cancer Drugs Market by Drug Class, Treatment Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年大肠直肠癌治疗市值为108.2亿美元，预计2024年将达到113.6亿美元，复合年增长率为5.12%，到2030年将达到153.6亿美元。

大肠直肠癌治疗市场包括针对大肠直肠癌（一种影响结肠和直肠的常见癌症）的治疗药物的研究、开发、製造和商业化。此细分市场包括多种产品，包括化疗、免疫疗法、标靶治疗和旨在增强治疗效果的小分子化合物。对大肠直肠癌药物的需求是由于这种疾病的高盛行率，开发有效的治疗方法以改善患者的预后和存活率至关重要。这些药物主要由肿瘤科医生、外科医生和专门从事肿瘤学的医疗机构在医院、专科诊所和研究机构使用。大肠直肠癌发生率上升、人口老化、医疗保健支出增加以及生物技术和分子诊断的进步是关键的成长动力，为製药公司创造了扩张机会。然而，严格的监管流程、高昂的治疗成本和潜在的副作用是市场成长的主要障碍。此外，来自生物相似药和学名药的竞争给药品价格带来压力并限制了利润率。个人化医疗、新型药物传递系统和联合治疗等领域的创新对于对抗抗药性和改善患者治疗效果至关重要。公司应投资于研发并考虑研究合作以促进创新。透过扩大新兴地区的准入范围，该市场显示出成长潜力，这些地区的意识提高和医疗基础设施的改善加速了药物的采用。此外，基因组学和蛋白​​质组学的技术进步为针对个别患者概况的个人化大肠癌治疗提供了机会。市场相关人员必须专注于加强供应链、优化定价策略、有效利用监管途径。总体而言，这个市场的动态性质要求能够灵活地应对技术进步和医疗保健政策的变化，为寻求创新和应对市场挑战的公司创造充满活力的业务，这表明存在机会。

主要市场统计
基准年[2023] 108.2亿美元
预测年份 [2024] 113.6亿美元
预测年份 [2030] 153.6亿美元
复合年增长率（%） 5.12%

市场动态：快速发展的结直肠癌药物市场的关键市场洞察

供需的动态交互作用正在改变大肠直肠癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球大肠直肠癌发生率迅速增加
    • 增加抗癌药物研发的投资和政府资助
    • 新药快速传播
  • 市场限制因素
    • 开发结肠癌药物成本高昂
  • 市场机会
    • 增加大肠直肠癌治疗的研究和开发
    • 网路药局和远端医疗设施的普及
  • 市场挑战
    • 用于高风险大肠直肠癌治疗的新辅助/辅助管道药物开发不足

波特五力：驾驭大肠直肠癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对大肠直肠癌药物市场的影响

外部宏观环境因素对大肠直肠癌治疗药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解大肠直肠癌治疗药物市场的竞争状况

对大肠直肠癌治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 大肠直肠癌治疗市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估大肠直肠癌治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘结直肠癌治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，结直肠癌治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 大肠直肠癌和直肠癌的发生率在世界各地迅速增加。
      • 增加对癌症药物开发的投资和政府资助
      • 新药快速引进
    • 抑制因素
      • 开发治疗大肠直肠癌的药物需要花费大量资金
    • 机会
      • 增加大肠直肠癌治疗的研发
      • 线上药局和远端医疗设施的激增
    • 任务
      • 缺乏用于治疗高风险大肠直肠癌的新药和术后辅助管线药物的开发
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 依药物类别分類的大肠直肠癌治疗药物市场

  • 抗血管新生药物
  • 化疗药物
  • 免疫治疗药物
  • 标靶治疗

第七章依治疗类型分類的大肠直肠癌治疗药物市场

  • 一线治疗
  • 二线治疗
  • 三线及以上治疗

第八章大肠直肠癌治疗药物市场：依给药途径

  • 静脉
  • 口服
  • 皮下的

第九章大肠直肠癌治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第十章 北美和南美大肠直肠癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区大肠直肠癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲大肠直肠癌治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 武田获得结直肠癌潜在治疗方法的批准
    • FDA加速核准图卡替尼合併曲妥珠单抗治疗大肠直肠癌
    • Carina Biotech 为大肠癌研究筹集资金
  • 战略分析和建议

公司名单

  • Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • HUTCHMED（China）Limited
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Marksans Pharma Ltd.
  • Merck & Co., Inc.
  • Mylan NV by Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • VolitionRx Limited
Product Code: MRR-431B7BFFBF56

The Colorectal Cancer Drugs Market was valued at USD 10.82 billion in 2023, expected to reach USD 11.36 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 15.36 billion by 2030.

The colorectal cancer drugs market encompasses the research, development, manufacturing, and commercialization of therapeutic drugs targeting colorectal cancer, a common cancer affecting the colon and rectum. This market segment includes a range of products such as chemotherapy, immunotherapy, targeted therapy, and small molecules designed to enhance treatment outcomes. The necessity for colorectal cancer drugs arises from the high prevalence of the disease, making it critical to develop effective treatments that improve patient prognosis and survival rates. These drugs find application within hospitals, specialty clinics, and research institutes, and are primarily used by oncologists, surgeons, and healthcare institutions focused on oncology. The rising incidence of colorectal cancer, coupled with an aging population, increasing healthcare expenditure, and advancements in biotechnology and molecular diagnostics, serve as key growth drivers, creating expansion opportunities for pharmaceutical companies. However, stringent regulatory processes, high treatment costs, and potential side effects pose significant barriers to market growth. Additionally, competition from biosimilars and generic drugs pressures drug pricing and limits profit margins. Innovation is essential in areas like personalized medicine, novel drug delivery systems, and combination therapies to address drug resistance and improve patient outcomes. Companies should invest in R&D and consider collaborations to expedite innovation. The market shows potential for growth through expanded access in emerging regions, where increasing awareness and better healthcare infrastructure can accelerate drug uptake. Additionally, technological advancements in genomics and proteomics present opportunities for personalized colorectal cancer drugs tailored to individual patient profiles. To thrive, market players must focus on bolstering supply chains, optimizing pricing strategies, and navigating regulatory pathways efficiently. Overall, the dynamic nature of this market requires agility in responding to technological advancements and shifts in healthcare policies, indicating vibrant opportunities for companies dedicated to innovating and addressing market challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 10.82 billion
Estimated Year [2024] USD 11.36 billion
Forecast Year [2030] USD 15.36 billion
CAGR (%) 5.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Colorectal Cancer Drugs Market

The Colorectal Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging prevalence of colon and rectal cancer worldwide
    • Increase in investments and government funding in development of cancer drugs
    • Rapid adoption of novel medicines
  • Market Restraints
    • High cost for developing colon cancer drugs
  • Market Opportunities
    • Increasing research and development studies for colorectal cancer treatment
    • Proliferation of online pharmacies and telehealth facilities
  • Market Challenges
    • Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer

Porter's Five Forces: A Strategic Tool for Navigating the Colorectal Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Colorectal Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Colorectal Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Colorectal Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Colorectal Cancer Drugs Market

A detailed market share analysis in the Colorectal Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Colorectal Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Colorectal Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Colorectal Cancer Drugs Market

A strategic analysis of the Colorectal Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Colorectal Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Limited by Intas Pharmaceuticals Ltd., Amgen Inc., Amneal Pharmaceuticals, Inc., Apotex Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, HUTCHMED (China) Limited, Lupin Limited, Mallinckrodt Pharmaceuticals, Manus Aktteva Biopharma LLP, Marksans Pharma Ltd., Merck & Co., Inc., Mylan N.V. by Viatris Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, and VolitionRx Limited.

Market Segmentation & Coverage

This research report categorizes the Colorectal Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-angiogenic Drugs, Chemotherapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs.
  • Based on Treatment Type, market is studied across First-Line Treatment, Second-Line Treatment, and Third-Line Treatment and Beyond.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of colon and rectal cancer worldwide
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Rapid adoption of novel medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost for developing colon cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research and development studies for colorectal cancer treatment
      • 5.1.3.2. Proliferation of online pharmacies and telehealth facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Colorectal Cancer Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-angiogenic Drugs
  • 6.3. Chemotherapy Drugs
  • 6.4. Immunotherapy Drugs
  • 6.5. Targeted Therapy Drugs

7. Colorectal Cancer Drugs Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. First-Line Treatment
  • 7.3. Second-Line Treatment
  • 7.4. Third-Line Treatment and Beyond

8. Colorectal Cancer Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Colorectal Cancer Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Colorectal Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Colorectal Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Colorectal Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Takeda to license potential treatment for colorectal cancer
    • 13.3.2. FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer
    • 13.3.3. Carina Biotech raises funds for colorectal cancer research
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • 2. Amgen Inc.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Apotex Inc.
  • 5. Bayer AG
  • 6. Bristol-Myers Squibb Company
  • 7. Eisai Co., Ltd.
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche Ltd
  • 10. GlaxoSmithKline PLC
  • 11. HUTCHMED (China) Limited
  • 12. Lupin Limited
  • 13. Mallinckrodt Pharmaceuticals
  • 14. Manus Aktteva Biopharma LLP
  • 15. Marksans Pharma Ltd.
  • 16. Merck & Co., Inc.
  • 17. Mylan N.V. by Viatris Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Sanofi S.A.
  • 22. Sumitomo Pharma Co., Ltd.
  • 23. Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. VolitionRx Limited

LIST OF FIGURES

  • FIGURE 1. COLORECTAL CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. COLORECTAL CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COLORECTAL CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ANTI-ANGIOGENIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD-LINE TREATMENT AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023